drugset / Trial / NCT02099864
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Phase 2
Completed
36 enrolled
OHSU Knight Cancer Institute
Astellas Pharma US, Inc. · collabOregon Health and Science University · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Studying samples of tissue and blood in the laboratory from patients with prostate cancer may help doctors better understand castration-resistant prostate cancer. It may also help doctors make improvements in prostate cancer treatment.
Timeline
- Start
- 2014-02-05
- Primary completion
- 2019-10-01
- Completion
- 2024-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | — | Oral |